Global Blood Therapeutics Reports Recent Business Progress

Global Blood Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, has reported business progress and financial results for the fourth quarter and year ended December 31, 2015.

Among the “2016 Anticipated Milestones” you will find:

  • Hereditary Angioedema: Complete IND-enabling toxicology studies, submit an IND, and initiate a Phase 1 study for GBT18713, an orally bioavailable kallikrein inhibitor.

(Source: Global Blood Therapeutics)